Ocular Therapeutix(TM) to Participate in March Investor Conferences

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is an integrated biopharmaceutical company dedicated to redefining treatments for retinal diseases. Based in Bedford, Massachusetts, Ocular is making strides in the field of ocular therapeutics with its innovative product pipeline. The company has announced its participation in several key investor conferences scheduled for March 2026, signaling its commitment to engage with the investment community and share insights into its developments and clinical progress.

Highlighted events include the TD Cowen 46th Annual Health Care Conference on March 2, where Dr. Pravin U. Dugel, Executive Chairman, President, and CEO, will present in a fireside chat. The company will also be participating in the Jefferies Biotech on the Beach Summit and the Citizens Life Sciences Conference on March 10 and 11, respectively, both also featuring Dr. Dugel. Following these, Ocular will engage virtually in the RBC Capital Markets Ophthalmology Conference on March 24.

Ocular Therapeutix's flagship investigational product, AXPAXLI™ (OTX-TKI), is currently in Phase 3 clinical trials aimed at treating wet age-related macular degeneration and diabetic retinal disease. The product utilizes the ELUTYX™ proprietary bioresorbable hydrogel technology. Additionally, the company offers DEXTENZA®, an FDA-approved corticosteroid that addresses ocular inflammation, pain following surgery, and allergic conjunctivitis. Ocular is also advancing its investigational product OTX-TIC, a hydrogel candidate aimed at treating open-angle glaucoma, which has completed Phase 2 trials.

For investors and media representatives seeking more information, live webcasts of select presentations will be accessible through Ocular's website for a month post-event. Ocular continues to be at the forefront of innovation in the retinal disease landscape.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) presents a compelling opportunity for investors as it prepares to participate in several key investor conferences in March 2026. The company's focus on redefining the retina experience through innovative biopharmaceutical solutions, particularly in the field of ophthalmology, positions it well within a growth sector marked by increasing demand for effective retinal disease treatments.

The participation of Dr. Pravin U. Dugel, Executive Chairman and CEO, in multiple fireside chats, including at the TD Cowen 46th Annual Health Care Conference and the Citizens Life Sciences Conference, offers investors a prime opportunity to gain insights directly from leadership regarding the company's strategic direction and milestones. With the ongoing Phase 3 clinical trials for AXPAXLI™ targeting wet age-related macular degeneration and diabetic retinal disease, the developments shared during these events could significantly impact the company’s stock performance. Positive updates might bolster investor confidence and drive the share price upward.

Furthermore, Ocular's existing product, DEXTENZA®, continues to generate revenue as an FDA-approved treatment for ocular inflammation and pain, which provides a revenue stream while the company advances its pipeline. The dual focus on both established products and cutting-edge investigational therapies, such as the travoprost intracameral hydrogel (OTX-TIC), indicates a robust development strategy that can appeal to diverse investor profiles.

Investors should also closely monitor market trends in ophthalmology, as the aging population and the prevalence of eye diseases continue to grow, creating a favorable environment for companies like Ocular Therapeutix. The upcoming conference presentations could be critical in shaping market sentiment around OCUL. Therefore, investors may consider taking a position in Ocular Therapeutix, particularly ahead of these pivotal events, to capitalize on potential growth outcomes that could arise from positive clinical trial results and strategic updates.